Literature DB >> 35003526

Two-Stage Adaptive Designs for Three-Treatment Bioequivalence Studies.

Michael J Grayling1,2, Adrian P Mander1,3, James M S Wason1,2.   

Abstract

Bioequivalence (BE) studies are most often conducted as crossover trials, and therefore establishing their required sample size necessitates specification of the within-person variance. Given that this specification is often difficult in practice, there has been great interest in recent years in the use of adaptive designs for BE trials. However, while numerous methods for this have now been presented, their focus has been solely on two-treatment BE studies. In some instances, it will be desired to incorporate more than a single test and reference formulation into a BE trial. It would therefore be useful to establish methodology for the design of adaptive multi-treatment BE trials, to acquire the benefits in the two-treatment setting in this more complex situation. Here, we achieve this for three-treatment studies by extending previously proposed designs for two-treatment trials. First, we discuss the additional design considerations that arise when multiple comparisons are made. Next, an extensive simulation study is employed to compare the performance of the proposed procedures. With this, we demonstrate that two-stage designs with desirable statistical operating characteristics can be readily identified for three-treatment BE trials. Supplementary materials for this article are available online.

Entities:  

Keywords:  Interim analysis; Re-estimation; Sequential; Unblinded

Year:  2019        PMID: 35003526      PMCID: PMC7612189          DOI: 10.1080/19466315.2019.1654911

Source DB:  PubMed          Journal:  Stat Biopharm Res        ISSN: 1946-6315            Impact factor:   1.452


  19 in total

1.  Simple procedures for blinded sample size adjustment that do not affect the type I error rate.

Authors:  Meinhard Kieser; Tim Friede
Journal:  Stat Med       Date:  2003-12-15       Impact factor: 2.373

2.  Optimal adaptive sequential designs for crossover bioequivalence studies.

Authors:  Jialin Xu; Charles Audet; Charles E DiLiberti; Walter W Hauck; Timothy H Montague; Alan F Parr; Diane Potvin; Donald J Schuirmann
Journal:  Pharm Stat       Date:  2015-11-05       Impact factor: 1.894

3.  Additional results for 'Sequential design approaches for bioequivalence studies with crossover designs'.

Authors:  Timothy H Montague; Diane Potvin; Charles E Diliberti; Walter W Hauck; Alan F Parr; Donald J Schuirmann
Journal:  Pharm Stat       Date:  2011-02-10       Impact factor: 1.894

4.  Modifications of sequential designs in bioequivalence trials.

Authors:  Cheng Zheng; Lihui Zhao; Jixian Wang
Journal:  Pharm Stat       Date:  2015-02-09       Impact factor: 1.894

5.  Two-stage designs for cross-over bioequivalence trials.

Authors:  Meinhard Kieser; Geraldine Rauch
Journal:  Stat Med       Date:  2015-03-24       Impact factor: 2.373

6.  An insight into the properties of a two-stage design in bioequivalence studies.

Authors:  Vangelis Karalis; Panos Macheras
Journal:  Pharm Res       Date:  2013-04-09       Impact factor: 4.200

7.  Sample size calculations for the development of biosimilar products.

Authors:  Seung-Ho Kang; Yongjo Kim
Journal:  J Biopharm Stat       Date:  2014       Impact factor: 1.051

8.  A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability.

Authors:  D J Schuirmann
Journal:  J Pharmacokinet Biopharm       Date:  1987-12

9.  Presentation of the intrasubject coefficient of variation for sample size planning in bioequivalence studies.

Authors:  D Hauschke; W V Steinijans; E Diletti; R Schall; H G Luus; M Elze; H Blume
Journal:  Int J Clin Pharmacol Ther       Date:  1994-07       Impact factor: 1.366

10.  An update on the clinical evidence that supports biosimilar approvals in Europe.

Authors:  Johanna Mielke; Bernd Jilma; Byron Jones; Franz Koenig
Journal:  Br J Clin Pharmacol       Date:  2018-04-27       Impact factor: 4.335

View more
  1 in total

1.  Innovative Design and Analysis for PK/PD Biosimilar Bridging Studies with Multiple References.

Authors:  Fuyu Song; Xin Zheng; Yujia Wang; Shein-Chung Chow; Hongqiang Sun
Journal:  AAPS J       Date:  2021-11-30       Impact factor: 4.009

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.